Understanding Respiratory Diagnosis 101, page-75

Dr Keating said at the TechKnow Invest Roadshow conference that ResApp had “perhaps not communicated well enough” in preparing investors for the news. “The results from the US are really positive, but I think we can understand that we haven’t educated shareholders well enough on what a good result actually looks like.  We can understand that the shareholders didn’t quite have the information to make that clear. We probably needed to bring to the forefront how complex the process is to have these clinical diagnoses assessed.”

 Yup a cut and paste : ) I have since read quite a few journal articles and some of the more informed posts here and I am coming round to accepting that Keating's statement was accurate. This is a very complex study and Resapp did not provide enough information for investors to fully understand the results and the implications for the future. The results do now appear more positive than I initially thought